- Home
- AMBP vs HCM Comparison
AMBP vs HCM Comparison
Compare AMBP & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMBP | HCM |
|---|---|---|
| Founded | 2021 | 2000 |
| Country | Luxembourg | Hong Kong |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AMBP | HCM |
|---|---|---|
| Price | $4.44 | $15.31 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 7 | 1 |
| Target Price | $4.39 | ★ $13.75 |
| AVG Volume (30 Days) | ★ 883.5K | 56.9K |
| Earning Date | 02-26-2026 | 03-18-2026 |
| Dividend Yield | ★ 9.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.53 |
| Revenue | ★ $5,346,000,000.00 | $602,197,000.00 |
| Revenue This Year | $13.08 | N/A |
| Revenue Next Year | $2.97 | $15.54 |
| P/E Ratio | ★ N/A | $5.71 |
| Revenue Growth | ★ 10.34 | N/A |
| 52 Week Low | $2.50 | $11.51 |
| 52 Week High | $4.78 | $19.50 |
Technical Indicators
Market Signals| Indicator | AMBP | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 63.83 | 58.62 |
| Support Level | $4.11 | $15.19 |
| Resistance Level | $4.42 | $15.82 |
| Average True Range (ATR) | 0.12 | 0.41 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 95.83 | 54.19 |
Price Performance
Historical ComparisonAbout AMBP Ardagh Metal Packaging S.A.
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. Its segment includes Europe and the Americas. It derives a majority of its revenue from the Americas.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.